CD8A and neoplasm: Similar results were seen with a triple therapy of MEK inhibitor, CDK4/6 inhibitor, and anti-PD-L1 also in a subcutaneous model; triple therapy improved DC antigen presentation, shifted the TME immune landscape to contain more lymphoid cells and fewer myeloid cells as well as enhanced anti-tumor macrophages, CD8 T cells and NK cells (147).